Skip to main content

Greenberg Traurig advises on sale of biotech company Targenomix to Bayer

Greenberg Traurig acted as sell-side advisor on the sale of German biotechnology company Targenomix GmbH to a Bayer AG group. Targenomix explores new mechanisms for crop protection solutions through novel biology and bioinformatics techniques. Bayer and Targenomix have been working together since 2014. Targenomix said it will continue to develop effective active ingredients to protect crops from weeds, diseases, and insects with Bayer as a strategic research partner. 

Greenberg Traurig's Mergers and Acquisitions (M&A) lawyers provided comprehensive sell-side advice on all relevant legal issues of the transaction including intellectual property matters. The parties agreed not to disclose the purchase price. 
The members of Greenberg Traurig's M&A team who focus on life sciences have recently advised on a number of relevant transactions in this area. The contact to the owner of Targenomix was established through a recommendation from a source in the market.


About Greenberg Traurig: Greenberg Traurig, LLP has more than 2500 attorneys in 43 locations in the United States, Europe, Latin America, Asia, and the Middle East. The firm reported gross revenue of over $2 Billion for FY 2021 and is consistently among the top firms on the Am Law 100, Am Law Global 100, and NLJ 250. On the debut 2022 Law360 Pulse Leaderboard, it is a Top 15 firm. Greenberg Traurig is Mansfield Rule 5.0 Certified Plus by The Diversity Lab and the Center for Resource Solutions Green-e® Energy program certifies that the firm’s U.S. offices are 100% powered by renewable energy. The firm is often recognized for its focus on philanthropic giving, innovation, diversity, and pro bono. Web: